Nirsevimab, a long-acting monoclonal antibody, was introduced last season (2023–2024) in some countries with the aim of ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...

Nirsevimab implementation in Catalonia, Spain, reduced emergency department visits and hospital admissions for bronchiolitis ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug ...

Clesrovimab joins the monoclonal antibody nirsevimab (Beyfortus), as well as the maternal bivalent RSV prefusion F protein ...

A single dose of the long-acting antibody nirsevimab to infants can halve hospitalizations for bronchiolitis. This is the ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

Real-world data from Madrid hospitals show dramatic declines in infant ICU stays, hospital days, and RSV-related admissions after nirsevimab immunization campaign. Study: Impact of Nirsevimab on ...

A single injection of nirsevimab, a long-acting monoclonal antibody developed to prevent respiratory syncytial virus (RSV) ...

Further, the study showed that nirsevimab’s effect was less pronounced in older children (between six and 23 months), ...

The World Health Organization (WHO) has published its first ever position paper on immunization against respiratory syncytial ...